Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTHEM, INC.

(ANTM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gynesonics Announces Anthem Issues Medical Necessity Coverage for the Treatment of Symptomatic Uterine Fibroids with the Sonata Procedure

09/14/2021 | 10:30am EDT

Gynesonics® announced Anthem, Inc. has provided positive payer coverage for the Sonata® Treatment. Anthem’s decision creates access for this minimally invasive procedure for women across the country, having the largest impact in California, New York, Georgia, Ohio, Virginia and Indiana. The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is an alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes and locations. Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved. Anthem is one of the country’s largest healthcare insurance plans and this policy validates the need for less invasive treatment options for women with systematic fibroids. Currently in the U.S. women will wait 3-5 years for treatment trying to avoid invasive surgery. As well, black women have the highest incidence of fibroid diagnoses, yet studies show they are least likely to be offered less invasive treatment options.


© S&P Capital IQ 2021
All news about ANTHEM, INC.
10/20Dow Jones Industrial Average : Strong earnings reports lift Wall Street
RE
10/20US Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings Impress
MT
10/20CLOSE UPDATE : US Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings ..
MT
10/20Brinker, Baker Hughes fall; Anthem, Abbott Laboratories rise
AQ
10/20Health Care Stocks Rally for Second Consecutive Day
MT
10/20Equities Advance Midday While Treasury Yields Remain Close to Highest Level Since May
MT
10/20Health Care Stocks Rally Second Consecutive Day
MT
10/20MIDDAY REPORT : US Stocks Advance While Treasury Yields Remain Close to Highest Level Sinc..
MT
10/20ANTHEM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
10/20Health insurer Anthem signals smaller pandemic hit next year
RE
More news
Analyst Recommendations on ANTHEM, INC.
More recommendations
Financials (USD)
Sales 2021 138 B - -
Net income 2021 6 138 M - -
Net Debt 2021 17 741 M - -
P/E ratio 2021 17,1x
Yield 2021 1,01%
Capitalization 103 B 103 B -
EV / Sales 2021 0,88x
EV / Sales 2022 0,79x
Nbr of Employees 83 400
Free-Float 99,3%
Chart ANTHEM, INC.
Duration : Period :
Anthem, Inc. Technical Analysis Chart | ANTM | US0367521038 | MarketScreener
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 424,05 $
Average target price 438,70 $
Spread / Average Target 3,45%
EPS Revisions
Managers and Directors
Gail Koziara Boudreaux President, Chief Executive Officer & Director
John Edward Gallina Chief Financial Officer & Executive Vice President
Elizabeth E. Tallett Independent Chairman
Gloria M. McCarthy Chief Administrative Officer & Executive VP
Ramiro G. Peru Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANTHEM, INC.22.63%103 390
UNITEDHEALTH GROUP21.02%400 155
CIGNA CORPORATION-0.74%70 276
HUMANA INC.7.61%56 735
CENTENE CORPORATION13.43%37 729
MOLINA HEALTHCARE, INC.36.40%16 464